Profile data is unavailable for this security.
About the company
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
- Revenue in USD (TTM)2.72m
- Net income in USD-85.08m
- Incorporated2016
- Employees75.00
- LocationShattuck Labs Inc500 W. 5Th Street, Suite 100AUSTIN 78701United StatesUSA
- Phone+1 (512) 900-4690
- Websitehttps://www.shattucklabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P3 Health Partners Inc | 1.35bn | -67.27m | 209.23m | 400.00 | -- | 0.4764 | -- | 0.1547 | -0.5855 | -0.5855 | 11.86 | 1.23 | 1.57 | -- | 11.40 | 3,381,965.00 | -21.31 | -- | -90.11 | -- | 1.59 | 0.1781 | -13.57 | -56.93 | -- | -10.05 | 0.2368 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
Outlook Therapeutics Inc | 0.00 | -159.13m | 209.48m | 24.00 | -- | -- | -- | -- | -11.48 | -11.48 | 0.00 | -6.10 | 0.00 | -- | -- | 0.00 | -281.52 | -214.69 | -2,060.72 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.75 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
Renovaro Inc | 0.00 | -53.93m | 212.41m | 11.00 | -- | 1.26 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 219.80m | 49.00 | -- | 4.95 | -- | 2,713.60 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Chromadex Corp | 83.17m | -3.53m | 219.82m | 106.00 | -- | 7.55 | -- | 2.64 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
Abeona Therapeutics Inc | 3.50m | -76.66m | 222.02m | 84.00 | -- | -- | -- | 63.43 | -3.20 | -3.20 | 0.1461 | -0.3224 | 0.0546 | -- | 2.54 | 41,666.67 | -119.62 | -53.22 | -140.83 | -65.81 | -- | -- | -2,190.26 | -1,894.25 | -- | -- | 1.97 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
Zura Bio Ltd | 0.00 | -60.18m | 223.11m | 14.00 | -- | 2.50 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Seres Therapeutics Inc | 126.85m | -82.68m | 224.14m | 233.00 | -- | -- | -- | 1.77 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
Shattuck Labs Inc | 2.72m | -85.08m | 225.39m | 75.00 | -- | 1.75 | -- | 83.02 | -1.93 | -1.93 | 0.0608 | 2.71 | 0.0168 | -- | -- | 36,200.00 | -52.52 | -29.14 | -57.94 | -32.42 | -- | -- | -3,133.63 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
Fractyl Health Inc | 148.00k | -83.16m | 226.07m | 102.00 | -- | 2.69 | -- | 1,527.52 | -1.73 | -1.73 | 0.0031 | 1.76 | -- | -- | -- | 1,450.98 | -- | -- | -- | -- | 37.16 | -- | -46,270.95 | -- | 9.37 | -5.10 | 0.2542 | -- | -- | -- | -48.15 | -- | -- | -- |
bluebird bio Inc | 21.73m | -91.17m | 232.23m | 323.00 | -- | 0.5867 | -- | 10.69 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
Acrivon Therapeutics Inc | 0.00 | -64.12m | 237.44m | 58.00 | -- | 1.61 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
Rezolute Inc | 0.00 | -58.21m | 238.42m | 51.00 | -- | 2.63 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
Caribou Biosciences Inc | 33.40m | -115.26m | 238.44m | 158.00 | -- | 0.6946 | -- | 7.14 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 7.12m | 14.97% |
Redmile Group LLCas of 21 Jun 2024 | 5.62m | 11.81% |
Prosight Management LPas of 31 Mar 2024 | 3.73m | 7.83% |
Adage Capital Management LPas of 31 Mar 2024 | 2.37m | 4.98% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.81m | 3.80% |
Franklin Advisers, Inc.as of 31 Mar 2024 | 1.66m | 3.50% |
The Clark Estates, Inc.as of 31 Mar 2024 | 1.48m | 3.10% |
Laurion Capital Management LPas of 31 Mar 2024 | 661.04k | 1.39% |
Millennium Management LLCas of 31 Mar 2024 | 612.38k | 1.29% |
Pinnacle Associates Ltd.as of 31 Mar 2024 | 521.25k | 1.10% |